



(51) International Patent Classification:

A61K 31/517 (2006.01) *C07D 239/72* (2006.01)
A61P 31/12 (2006.01) *C07D 239/84* (2006.01)
C07C 309/30 (2006.01)

(21) International Application Number:

PCT/US2016/062654

(22) International Filing Date:

18 November 2016 (18.11.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/259,167 24 November 2015 (24.11.2015) US

(71) Applicant: MERCK SHARP & DOHME CORP.

[US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and

(71) Applicants (for US only): CHUNG, Cheol, K. [KR/US];

126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

HUMPHREY, Guy, R. [US/US]; 126 East Lincoln Avenue,

Rahway, NJ 07065-0907 (US). LIU, Zhijian [CN/US];

126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

MCLAUGHLIN, Mark [US/US]; 126 East Lincoln Avenue,

Rahway, NJ 07065-0907 (US). XU, Yingju

[US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-

0907 (US). YU, Younong [US/US]; 2000 Galloping Hill

Road, Kenilworth, NJ 07033 (US).

(74) Common Representative: MERCK SHARP & DOHME

CORP.; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS USING HYDROGEN BONDING CATALYSTS



(57) Abstract: Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.

WO 2017/091453 A1



Published:

— *with international search report (Art. 21(3))*

TITLE OF THE INVENTION

NOVEL PROCESSES FOR MAKING SUBSTITUTED QUINAZOLINE COMPOUNDS
USING HYDROGEN BONDING CATALYSTS


5 FIELD OF THE INVENTION

The present invention is directed to novel processes for making substituted quinazoline compounds which are useful for the treatment or prophylaxis of HCMV infection.

10 BACKGROUND OF THE INVENTION

Human cytomegalovirus (HCMV) is ubiquitously distributed in the human population. In immunocompetent adults infections are mainly asymptomatic, but in immunocompromised patients, such as transplant recipients or AIDS patients, life threatening infections occur at a high rate. HCMV is also the leading cause of birth defects among
15 congenitally transmitted viral infections.

Various substituted heterocyclic compounds are inhibitors of the HCMV terminase enzyme. Included in these heterocycles are quinazolines related to Compound A, as defined and described below. These compounds and pharmaceutically acceptable salts thereof are useful in the treatment or prophylaxis of infection by HCMV and in the treatment,
20 prophylaxis, or delay in the onset or progression of HCMV infection. Representative quinazoline compounds that are useful for treating HCMV infection are described, for example, in US Patent Patent No. 7,196,086. Among the compounds disclosed in US7,196,086, is (S)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid, hereinafter referred to
25 as Compound A. Compound A is a known inhibitor of HCMV terminase. The structure of Compound A is as follows:




Compound A


US Patent Nos. 7,196,086 and 8,084,604 and PCT Publication No. WO2015/088931 disclose methodology and synthetic routes that can be used to prepare Compound A and related quinazoline-based HCMV terminase inhibitors. However, the currently known methods have various drawbacks and there remains a need for improved synthetic methods for preparing Compound A and related compounds.

SUMMARY OF THE INVENTION

Disclosed herein are novel processes for making substituted quinazoline compounds of Formula (I) which are useful for the treatment and prophylaxis of HCMV infection. Specifically, these processes use various hydrogen bonding catalysts disclosed herein for the preparation of compounds of Formula I:



In one embodiment, a process for preparing a compound of formula (I) comprises contacting a compound of formula (viii):



or a salt thereof, with a hydrogen bonding catalyst in a suitable solvent for a time sufficient to form a compound of formula (I), wherein:

R^1 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, -CN, -OH and C_1 - C_6 alkoxy;

R^2 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, -CN, -OH and C_1 - C_6 alkoxy;


R^3 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, -CN, -OH and C_1 - C_6 alkoxy; and

R^4 is C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl.


DETAILED DESCRIPTION OF THE INVENTION

Disclosed herein are processes using novel hydrogen bonding catalysts for making substituted quinazoline compounds of Formula (I) which are useful for inhibiting the replication of HCMV and for the treatment or prophylaxis of HCMV infection.

In one embodiment, a process for preparing a compound of formula (I):



comprises contacting a compound of formula (viii):



or a salt thereof, with a hydrogen bonding catalyst in a suitable solvent for a time sufficient to form a compound of formula (I), wherein:

R^1 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, -CN, -OH and C_1 - C_6 alkoxy;

R^2 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, -CN, -OH and C_1 - C_6 alkoxy;

R^3 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, -CN, -OH and C_1 - C_6 alkoxy; and


R^4 is C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl.

The use of the instant hydrogen bonding catalysts is novel for this type of transformation and the instant processes are more simplified compared to known processes. In one embodiment, the instant processes have the unexpected advantage of producing compounds of formula (I) with higher enantiomeric excess (ee). Enantiomeric excess is a

measurement of purity used for chiral substances. It reflects the degree to which a sample contains one enantiomer in greater amounts than the other. For example, a racemic mixture has an ee of 0%, while a single completely pure enantiomer has an ee of 100%. A sample with 70% of one enantiomer and 30% of the other has an ee of 40%.

5 In one embodiment, the instant processes have the unexpected advantage of producing compounds of formula (I) with higher yields.

In one embodiment, the hydrogen bonding catalyst is a bis-triflate compound of formula (V):




10 each occurrence of R^5 is independently selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and C_1 - C_6 alkyl optionally substituted with one to four halogens; and

each occurrence of R^6 is independently selected from the group consisting of –
 15 SO_2 - C_1 - C_6 alkyl optionally substituted with one to nine halogens, – SO_2 -aryl, – SO_2 -heteroaryl, and nonaflate (“Nf”).

In one embodiment, each occurrence of R^5 is independently selected from the group consisting of phenyl, naphthyl and pyridine; wherein each of the phenyl and naphthyl is optionally substituted with one to three substituents independently selected from halogen, –
 20 O - C_1 - C_4 alkyl, –CN, sulfonate, – NO_2 , phosphonate, C_1 - C_4 alkyl optionally substituted with one to four halogens, – O -Tf, and – O -Ts- CF_3 .


In one embodiment, each occurrence of R^6 is independently selected from the group consisting of triflate (“Tf”) and nonaflate (“Nf”). In one embodiment, each occurrence of R^6 is Tf. In one embodiment, each occurrence of R^6 is Nf.

25 In one embodiment, the catalyst of formula (V) is a compound of formula (Va):




wherein substituents R^5 and R^6 are as defined above for formula (V).

In one embodiment, the catalyst of formula (V) or (Va) is a compound selected from the group consisting of:



5 In one embodiment, a hydrogen bonding catalyst is a compound of formula (VI):




wherein each occurrence of R^7 is independently selected from the group consisting of halogen, C_1 - C_6 alkyl optionally substituted with one to four halogens, C_1 - C_6 alkoxy, optionally substituted aryl, and optionally substituted heteroaryl; and
 10 each occurrence of R^8 is independently selected from the group consisting of hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halo- C_1 - C_6 alkyl, optionally substituted aryl, and optionally substituted heteroaryl.

In one embodiment, each occurrence of R^7 is independently selected from the group consisting of phenyl, naphthyl, phenanthrenyl, pyridyl and thiophenyl, each of which is optionally substituted with one to five substituents independently selected from halogen and - CF_3 .

5 In one embodiment, each occurrence of R^8 is hydrogen.

In one embodiment, the catalyst of formula (VI) is a compound selected from the group consisting of:



10 In one embodiment, a suitable solvent for a bis-triflate or binol catalyzed reaction to obtain a compound of formula (I) is selected from the group consisting of acetone, toluene, CF_3 -toluene, dichloromethane, DCE, THF, chlorobenzene, 1,2-dichlorobenzene, MTBE, cyclopentyl methyl ether (CPME), acetonitrile, EtOAc, IPAc, MeOAc, nitromethane, trifluoromethylbenzene, methyl ethyl ketone, DME, anisole, hexafluorobenzene, o-xylene,
15 fluorobenzene, 1,4-dioxane, iPr_2O and 2-MeTHF.

In one embodiment, the solvent used for a bis-triflate catalyzed reaction is toluene, MTBE or CPME.

In one embodiment, the solvent used for a binol catalyzed reaction is CF_3 -toluene, chlorobenzene or 1,2-dichlorobenzene.

In one embodiment, a reaction to obtain a compound of formula (I) is carried out at a temperature of from about 5°C to about 80°C when a catalyst of formula (V) or (Va) is used. In another embodiment, the temperature is in a range from about 10°C to about 70°C. In another embodiment, the temperature is in a range from about 20°C to about 60°C.


5 In another embodiment, the temperature is in a range from about 25°C to about 50°C.

In one embodiment, a reaction to obtain a compound of formula (I) is carried out at a temperature in a range from about 30°C to about 100°C when a catalyst of formula (VI) is used. In another embodiment, the temperature is in a range from about 40°C to about 90°C.

10 In another embodiment, the temperature is in a range from about 50°C to about 80°C. In another embodiment, the temperature is in a range from about 50°C to about 70°C. In another embodiment, the temperature is about 55°C to about 65°C.

In one embodiment, the catalysts disclosed herein are more stable compared to known catalysts for this type transformation. In another embodiment, these catalysts are
15 recyclable and more environmentally friendly.

In one embodiment, the compound of formula (I) that is made by the above processes is the compound of formula (III):



The starting material, a compound of formula (viii), can be readily prepared,
20 for example, as described in PCT Application No. PCT/US14/068981 published as WO2015/088931.

Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples, and appended claims.

25

Definitions and Abbreviations

The term "alkyl" as used herein, refers to an aliphatic hydrocarbon group, having from 1 to 20 carbon atoms wherein one of its hydrogen atoms is replaced with a bond. An alkyl group may be straight or branched. In one embodiment, an alkyl group has from 1-6

carbon atoms ("C₁-C₆alkyl"). In another embodiment, an alkyl group has from 1-4 carbon atoms ("C₁-C₄alkyl"). Non-limiting examples of C₁-C₆ alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl, isohexyl and neohexyl. Non-limiting examples of C₁-C₄ alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl. An alkyl group may be unsubstituted or substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl, cyano, hydroxy, -O-alkyl, -O-aryl, -alkylene-O-alkyl, alkylthio, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(cycloalkyl), -O-C(O)-alkyl, -O-C(O)-aryl, -O-C(O)-cycloalkyl, -C(O)OH and -C(O)O-alkyl. In one embodiment, a C₁-C₆ alkyl group is linear. In another embodiment, a C₁-C₆ alkyl group is branched. Unless otherwise indicated, a C₁-C₆ alkyl group is unsubstituted.

The term "alkenyl," as used herein, refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and having one of its hydrogen atoms replaced with a bond. An alkenyl group may be straight or branched and contain from about 2 to about 15 carbon atoms. In one embodiment, an alkenyl group contains from about 2 to about 12 carbon atoms. In another embodiment, an alkenyl group contains from about 2 to about 6 carbon atoms ("C₂-C₆ alkenyl"). Non-limiting examples of alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl. An alkenyl group may be unsubstituted or substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl, cyano, hydroxy, -O-alkyl, -O-aryl, -alkylene-O-alkyl, alkylthio, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(cycloalkyl), -O-C(O)-alkyl, -O-C(O)-aryl, -O-C(O)-cycloalkyl, -C(O)OH and -C(O)O-alkyl. The term "C₂-C₆ alkenyl" refers to an alkenyl group having from 2 to 6 carbon atoms. Unless otherwise indicated, an alkenyl group is unsubstituted.


The term "alkynyl," as used herein, refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and having one of its hydrogen atoms replaced with a bond. An alkynyl group may be straight or branched and contain from about 2 to about 15 carbon atoms. In one embodiment, an alkynyl group contains from about 2 to about 12 carbon atoms. In another embodiment, an alkynyl group contains from about 2 to about 6 carbon atoms. Non-limiting examples of alkynyl groups include ethynyl, propynyl, 2-butyne and 3-methylbutynyl. An alkynyl group may be unsubstituted or substituted by one

or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkenyl, alkynyl, aryl, cycloalkyl, cyano, hydroxy, -O-alkyl, -O-aryl, -alkylene-O-alkyl, alkylthio, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(cycloalkyl), -O-C(O)-alkyl, -O-C(O)-aryl, -O-C(O)-cycloalkyl, -C(O)OH and -C(O)O-alkyl. The term "C₂-C₆ alkynyl" refers to an alkynyl group having from 2 to 6 carbon atoms. Unless otherwise indicated, an alkynyl group is unsubstituted.

The term "C₁-C₆ hydroxyalkyl" as used herein, refers to C₁-C₆ alkyl group, as defined above, wherein one of the C₁-C₆ alkyl group's hydrogen atoms is replaced with a -OH group. A C₁-C₆ hydroxyalkyl group may be straight or branched and contain. Non-limiting examples of C₁-C₆ hydroxyalkyl groups include methanol, ethanol, isopropanol, and tert-butanol.

The term "aryl" refers to phenyl, naphthyl or phenanthrenyl. In one embodiment, an aryl group is phenyl. In one embodiment, an aryl group is naphthyl. In one embodiment, an aryl group is phenanthrenyl.

The term "3 to 7-membered cycloalkyl" refers to a refers to a non-aromatic mono- or ring system comprising from about 3 to about 7 ring carbon atoms. Examples of "3 to 7-membered cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A 3 to 7-membered cycloalkyl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein below. In one embodiment, a 3 to 7-membered cycloalkyl group is unsubstituted. A ring carbon atom of a 3 to 7-membered cycloalkyl may be functionalized as a carbonyl group. An illustrative example of such a 3 to 7-membered cycloalkyl (also referred to herein as a "cycloalkanoyl" group) includes, but is not limited to, cyclobutanoyl:



The term "halo" or "halogen" as used herein, refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).

The term "5 or 6-membered monocyclic heteroaryl," as used herein, refers to an aromatic monocyclic ring system comprising about 5 to about 6 ring atoms, wherein from 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms. A 5 or 6-membered monocyclic heteroaryl group can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein below. A 5 or 6-membered monocyclic heteroaryl group is joined via a ring carbon

atom, and any nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. The term "5 or 6-membered monocyclic heteroaryl" also encompasses a 5 or 6-membered monocyclic heteroaryl group, as defined above, which is fused to a benzene ring. Non-limiting examples of 5 or 6-membered monocyclic heteroaryls include pyridyl, 5 pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, imidazolyl, benzimidazolyl, thienopyridyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolyl, 1,2,4-triazinyl, benzothiazolyl and the like, and 10 all isomeric forms thereof. Unless otherwise indicated, a 5 or 6-membered monocyclic heteroaryl group is unsubstituted.

The term "9 or 10-membered bicyclic heteroaryl," as used herein, refers to an aromatic bicyclic ring system comprising about 9 to about 10 ring atoms, wherein from 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms. 15 A 9 or 10-membered bicyclic heteroaryl group can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein below. A 9 or 10-membered bicyclic heteroaryl group is joined via a ring carbon atom, and any nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of 9 or 10-membered bicyclic heteroaryls include and the like, and all 20 isomeric forms thereof. Unless otherwise indicated, a 9 or 10-membered bicyclic heteroaryl group is unsubstituted.

Unless expressly stated to the contrary in a particular context, any of the various cyclic rings and ring systems described herein may be attached to the rest of the compound of which they are a part at any ring atom (*i.e.*, any carbon atom or any heteroatom) 25 provided that a stable compound results.

Unless expressly stated to the contrary, all ranges cited herein are inclusive; *i.e.*, the range includes the values for the upper and lower limits of the range as well as all values in between.

When any variable occurs more than one time in a compound involved in the 30 process of the invention (*e.g.*, R^f), its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in a stable compound.


Unless expressly stated to the contrary, substitution by a named substituent is permitted on any atom in a ring (*e.g.*, cycloalkyl, aryl, or heteroaryl) provided such ring substitution is chemically allowed and results in a stable compound.

In reference to the compounds employed as reactants or reagents in the process of the invention, a "stable" compound is one whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow its use in the process of the invention so as to achieve the preparation of Compound of Formula (I). In reference to Compound of Formula (I), a "stable" compound is a compound which can be prepared in accordance with the process of the present invention and then isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for its intended purpose; *e.g.*, for the therapeutic administration to a subject who has HCMV infection.

The following abbreviations are used below and have the following meanings: Ac is acetyl; t-Bu is tertiary butyl; DCB is 1,2-dichlorobenzene; DCE is 1,2-dichloroethane; DCM is dichloromethane; DMAP is N,N-dimethylaminopyridine; DME is dimethoxyethane; DTTA is di-P-toluoyl-D-tartaric acid; EA is ethyl acetate; Et is ethyl; HPLC is high performance liquid chromatography; IPAC is isopropyl acetate; i-Pr is isopropyl; LC/MS is liquid chromatography/Mass Spectrometry; Me is methyl; MTBE is methyl tert-butyl ether; Ph is phenyl; pin is pinacol; THF is tetrahydrofuran; TLC is thin-layer chromatography and Ts is p-toluenesulfonate.


EXPERIMENTAL

In one embodiment, reactions were carried out with the bis-triflate catalyst as shown below at about 50 °C using different solvents shown in the following table. The conversion rate (%) and % e.e. for each reaction is included in the table.



Solvent	Conversion	e.e. (%)		Solvent	Conversion	e.e. (%)
hexafluorobenzene	100%	51%		MTBE	100%	86%
octafluorotoluene	100%	72%		2-MeTHF	95%	85%
toluene	100%	83%		THF	53%	84%
o-xylene	100%	82%		DME	99%	87%
F-Ph	100%	83%		EtOAc	88%	87%
Cl-Ph	100%	82%		IPAC	88%	87%
1,2-DCB	100%	80%		DCE	100%	81%
CF ₃ -Ph	100%	79%		acetone	99%	80%
1,4-dioxane	58%	85%		cyclopentanone	89%	51%
iPr ₂ O	60%	70%		cyclohexanone	100%	26%
anisole	100%	86%		PhCN	100%	79%
CPME	100%	85%		MeCN	100%	69%


In one embodiment, reactions were carried out with the binol catalyst as shown below at about 60°C using different solvents shown in the following table. The conversion rate (%) and % e.e. for each reaction is included in the table.











Solvent	Conversion	e.e. (%)
Toluene	70%	70%
C ₆ F ₆	98%	68%
CPME	34%	35%
Anisole	51%	55%
Cl-Ph	79%	72%
F-Ph	83%	70%
2MeTHF	12%	27%
IPAC	28%	24%




DME	25%	4%
1,2-Cl ₂ -Ph	88%	75%
CF ₃ -Ph	99%	76%
Ph-CN	70%	17%

In one embodiment, each reaction was carried out with a different catalyst shown in the following table at about 35°C to about 50°C. Solvents used and the corresponding % e.e.'s are included in the table.










Catalyst	ee% (EA)	ee% (Toluene)	ee% (CPME)	ee% (MTBE)	ee% (Anisole)	ee% (2-MeTHF)
	88	83	85	86	86	85
	-86	-86	-86	-86		
			-91			
		-86.6		-93.5		

			90			
	81	82	92	92		
	90	89	93	93	92	
	85	89	92	93		
	89	87	91	92		
	80	71	81	82		
	77	67	73		73	
	84					


	75	79	72			
	90	87	90	91		
	76	79	88		87	

In one embodiment, each reaction was carried out with a different catalyst shown in the following table at about 50°C to about 80°C using Cl-benzene as solvent. The corresponding % e.e.'s are included in the table.

Catalyst	% e.e. (Cl-benzene)	% e.e. (CF ₃ -benzene)
	80	
	45	


	80	
	40	
	72	
	72	
	77	

In one embodiment, disclosed herein is a process for making a compound of Formula (II):




comprising the steps of:

- 5 (A) contacting a compound of formula (I):



with di-p-toluoyl-D-tartaric acid in a mixture of organic solvent D and ethyl acetate for a time sufficient to form a compound of formula (ix):



wherein organic solvent D is selected from ethyl acetate, isopropyl acetate, THF, 2-methyltetrahydrofuran, DCM, benzene, toluene, xylene, chlorobenzene, dioxane, and a mixture thereof; and

- 15 (B) (i) contacting the compound of Formula (ix) with a phosphate or hydrogen phosphate base in water; (ii) contacting the product of step (i) with an alkali metal hydroxide base in a mixture of water, an organic solvent D' and an organic solvent D''; (iii) acidifying the solution of step (ii) using an acid; and (iv) concentrating the solution of step (iii), taking up the concentrate in acetone, and adding the resulting solution to water and collecting the precipitate formed to provide a compound of Formula (II), wherein organic

solvent D' is an organic alcohol, and organic solvent D'' is an organic ether or THF, and wherein:

R¹ represents up to 3 phenyl group substituents, each independently selected from C₁-C₆ alkyl, C₁-C₆ haloalkyl, halo, -CN, -OH and C₁-C₆ alkoxy;


5 R² represents up to 3 phenyl group substituents, each independently selected from C₁-C₆ alkyl, C₁-C₆ haloalkyl, halo, -CN, -OH and C₁-C₆ alkoxy;

R³ represents up to 3 phenyl group substituents, each independently selected from C₁-C₆ alkyl, C₁-C₆ haloalkyl, halo, -CN, -OH and C₁-C₆ alkoxy; and

R⁴ is selected from C₁-C₆ alkyl, and C₃-C₇ cycloalkyl.

10 In one embodiment of the above process, each occurrence of R¹ is halo; each occurrence of R² is independently selected from halo, C₁-C₃ alkyl, C₁-C₃ alkoxy and C₁-C₃ haloalkyl; each occurrence of R³ is independently selected from C₁-C₃ alkyl and C₁-C₃ alkoxy; and R⁴ is C₁-C₆ alkyl.

15 In one embodiment, the compound of formula (II) that is made by the above process is Compound A:




EXAMPLES

General Methods

20 Solvents, reagents, and intermediates that are commercially available were used as received. Reagents and intermediates that are not commercially available were prepared in the manner as described below. ¹H NMR spectra were obtained on a Bruker Avance NMR Spectrometer and are reported as ppm downfield from Me₄Si with number of protons, multiplicities, and coupling constants in Hertz indicated parenthetically. Where
25 LC/MS data are presented, analyses was performed using an Applied Biosystems API-100 mass spectrometer and Shimadzu SCL-10A LC column: Altech platinum C18, 3 micron, 33 mm x 7mm ID; gradient flow: 0 minutes – 10% CH₃CN, 5 minutes – 95% CH₃CN, 5-7

minutes – 95% CH₃CN, 7 minutes – stop. The retention time and observed parent ion are given.

Example 1: Preparation of Compound 3




5

Compound 1 (4.05 g; 6.90 mmol) was charged into a 40 mL vial followed by the catalyst (0.285 g; 81 wt%; 0.299 mmol). To the mixture was charged MTBE (12 ml), and the slurry was heated at 35°C. HPLC was used to monitor the reaction and it indicated > 99.9 % conversion to Compound 2 after 24 hours with 92.7 % ee. It was concentrated and solvent-switched to toluene. To the resulting toluene solution of crude reaction mixture (ca. 34 ml) was added (S,S)-DTTA (2.67 g; 6.90 mmol) in 6 mL EtOAc. The mixture was stirred at room temperature for 24 hours. The slurry was then filtered, and the collected solid was rinsed with EtOAc, and dried under vacuum to give 6.60 g (90% isolated yield) Compound 3 as its DTTA salt ethyl acetate solvate. ¹H NMR (500 MHz, d₆-DMSO): δ_H 13.95 (2H, br s), 7.90 (4H, d, *J* = 8.1 Hz), 7.55 (1H, dd, *J* = 8.6, 1.3 Hz), 7.38 (4H, d, *J* = 8.1 Hz), 7.26 (1H, d, *J* = 7.8 Hz), 7.09-7.05 (3H, m), 6.91-6.86 (2H, m), 6.44 (1H, dd, *J* = 8.2, 1.7 Hz), 6.39 (1H, t, *J* = 2.0 Hz), 6.36 (1H, dd, *J* = 8.2, 2.0 Hz), 5.82 (2H, s), 4.94 (1H, t, *J* = 7.1 Hz), 4.02 (2H, q, *J* = 7.1 Hz), 3.83 (3H, br s), 3.68 (3H, s), 3.64 (3H, s), 3.47 (2H, br s), 3.37 (2H, br s), 2.95 (2H, br s), 2.87-2.80 (3H, m), 2.56 (1H, dd, *J* = 14.3, 7.0 Hz), 2.39 (6H, s), 1.98 (3H, s), 1.17 (3H, t, *J* = 7.1 Hz).

10


15

20

Example 2: Preparation of Compound 3


Compound 1 (5.00 g, 8.52 mmol) was charged into a 40-mL vial followed by catalyst (0.207 g, 0.426 mmol). To the mixture was charged MTBE (15 ml), and the slurry was then heated at 50°C. HPLC was used to monitor the reaction and it indicated > 99.9 % conversion after 24 hours with 84.6 % ee. It was concentrated and solvent-switched to toluene. To the toluene solution of crude reaction mixture (ca. 40 ml) was added (s,s)-DTTA (3.36 g; 8.52 mmol) in 5 mL EtOAc. The mixture was stirred and aged at room temperature for 24 hours. The white slurry was filtered and the collected solid was rinsed with EtOAc, and dried under vacuum to give 8.05 g (89% isolated yield) Compound 3 as its DTTA salt ethyl acetate solvate.

Example 3: Preparation of Compound 3



Compound 1 (4.00 g; 6.82 mmol) and catalyst (0.29 g; 0.50 mmol) were charged into a 100-mL three-neck round-bottom flask equipped with a condenser and an overhead stirrer. To the mixture was charged toluene (32 ml), and the slurry was then heated at 35°C. HPLC was used to monitor the reaction and it indicated > 99.9 % conversion after 36 hours with – 84.8 % ee. At 35°C, to the clear reaction mixture was added (R,R)-DTTA (2.63 g; 6.82 mmol) in 8 mL EtOAc. The mixture was cooled to 2-3°C over 5 hours and then aged at 2-3°C overnight. The slurry was filtered, and the collected solid was rinsed with EtOAc. The wet cake was dried to give 6.48 g (90% isolated yield) Compound (-)-3 as its DTTA salt ethyl acetate solvate

Example 4: Preparation of Compound 2




Compound 1 (1 g; 1.7 mmol) was charged into a 40-mL vial followed by catalyst (0.121 g; 0.17 mmol). To the mixture was charged CF₃-benzene (10 ml), and the


reaction was then heated at 50°C. Compound 2 was obtained after 66 hours with 95% conversion and 80 % e.e.

Catalyst Preparations

- 5 In one embodiment, the bistriflate catalyst having the following structure can be obtained from Oakwood Products, Inc. at 730 Columbia Hwy. N, Estill, SC 29918.




In one embodiment, a process for preparing the following catalyst is shown below.



10


- To a cooled solution of diamine HCl salt (0.22g, 0.57 mmol) in DCM (4.4 ml) was added TEA (5.0 eq, 0.29 g, 2.85 mmol) and DMAP (0.1 eq, 7 mg, 0.057 mmol). To the resulting mixture was added TiF_2O solution in DCM (1M, 2.2 eq, 1.26 ml) dropwise maintaining the reaction temperature below -50 °C. After stirring at the same temperature for
- 15 10 min, the reaction mixture was allowed to warm to room temperature slowly over 30 min. The reaction was poured into 4% NaHCO_3 aq. solution and extracted with DCM (5 ml x 2). The combined organic layer was washed with 1N HCl followed by brine. After drying over Na_2SO_4 , the crude product was purified by column chromatography on silica to afford the desired bistriflate as a white solid (0.28g, 0.48 mmol, Y = 84%). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.75 (s, 2H), 7.95 (d, J = 7.3 Hz, 4H), 7.59 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.1 Hz, 4H), 7.31 (t, J = 7.5 Hz, 2H), 7.16 (t, J = 7.7 Hz, 2H), 5.95 (s, 2H). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 133.4, 132.3, 129.7, 128.3, 128.3, 125.9, 125.3, 125.2, 124.6, 122.2, 119.0 (q, J = 322.1 Hz), 57.4. ^{19}F NMR (471 MHz, $\text{DMSO}-d_6$) δ -77.78.
- 20

- In one embodiment, a process for preparing the following catalyst is shown below.
- 25




Following a similar procedure as the above example, diamine HCl salt (0.52g, 1.45 mmol) was transformed to bistriflate (0.55g, 1.00 mmol, Y = 69%) as white solid. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.75 (s, 2H), 7.72 (q, J = 8.0 Hz, 2H), 7.13 (td, J = 8.5, 2.6 Hz, 2H), 7.05 – 6.96 (m, 2H), 5.09 (d, J = 3.5 Hz, 2H). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 162.5 (dd, J = 248.4, 12.4 Hz), 158.9 (dd, J = 248.5, 12.4 Hz), 130.2 (d, J = 8.6 Hz), 121.1 (q ??), 121.0 (d, J = 13.9 Hz), 112.6 (d, J = 21.5 Hz), 103.7 (t, J = 26.4 Hz), 55.0. ^{19}F NMR (471 MHz, $\text{DMSO}-d_6$) δ -77.90, -108.69, -113.47.

In one embodiment, a process for preparing the following catalyst is shown below.



Following a similar procedure as the above example, diamine HCl salt (0.2g, 0.53 mmol) was transformed to bistriflate (0.2g, 0.35 mmol, Y = 66%) as white solid. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.98 (s, 2H), 7.97 (q, J = 7.8 Hz, 2H), 7.72 (td, J = 7.8, 1.3 Hz, 2H), 7.66 (dd, J = 8.2, 1.3 Hz, 2H), 7.47 (td, J = 8.0, 1.3 Hz, 2H), 5.87 (s, 2H). ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 147.6, 134.6, 130.9, 130.6, 129.6, 125.1, 119.5 (q, J = 318.7 Hz), 56.8. ^{19}F NMR (470 MHz, $\text{DMSO}-d_6$) δ -77.80.


In one embodiment, a process for preparing the following catalyst is shown below.



To a stirring mixture of diamine compound (0.200 g, 0.819 mmol), NEt_3 (0.340 g, 3.36 mmol), DMAP (0.0020 g, 0.016 mmol) and CH_2Cl_2 (7 ml) chilled to less than -40°C was added dropwise nonafluorobutanesulfonic anhydride (1.95 g, 3.36 mmol). When


complete the reaction mixture was poured into a 1:1 mixture of saturated NaHCO_3 and water. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 . The organic layers were combined and washed with 1N HCl and water, dried with Na_2SO_4 and filtered. The filtrate was concentrated under vacuum and purified on silica to give catalyst as a solid (0.689 g, 0.819 mmol, Y = 61%). ^1H NMR (500 MHz, acetonitrile- d_3): δ 8.21 (br s, 2H), 7.79 (dd, J = 7.8 Hz, 1.3 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.42 (t, J = 8.5 Hz, 2H), 7.10 (d, J = 8.3 Hz, 2H), 5.30 (s, 2H). ^{13}C NMR (126 MHz, DMSO- d_6): δ 146.1, 131.5, 129.2, 129.0, 128.1, 120.1, 56.8 [High order coupling of Nf cannot be resolved due to signal to noise ratio]. ^{19}F NMR (471 MHz, DMSO- d_6): δ -81.5 (t, J = 9.4 Hz), -81.7 (t, J = 9.4 Hz), -110.0 (m), -113.5 (t, J = 9.4 Hz), -121.4, -121.8, -126.3 (t, J = 14.1 Hz), -126.7 (t, J = 14.1 Hz).

In one embodiment, a process for preparing the following catalyst is shown below.




To a stirring mixture containing a diamine compound (0.500 g, 2.36 mmol), NEt_3 (0.953 g, 9.42 mmol), DABCO (0.013 g, 0.12 mmol) and acetonitrile (8 ml) cooled in an ice bath was added dropwise perfluoro-1-butananesulfonyl fluoride (1.71 g, 5.65 mmol). When complete the reaction was poured into 1:1 mixture of saturated NaHCO_3 and water and extracted with ethyl acetate. The aqueous layer was cut away and the organic layer was washed with 1N HCl and water, dried with sodium sulfate and filtered. The filtrate was concentrated under vacuum and purified on silica to give catalyst as a solid (1.34 g, 1.73 mmol, Y = 73 %). ^1H NMR (500 MHz, DMSO- d_6): 10.51 (br s, 2H), 7.14-7.09 (m, 10H), 4.73-4.71 (m, 2H). ^{13}C NMR (126 MHz, DMSO- d_6): δ 137.4, 128.0, 127.7, 127.3, 64.1 [Higher order coupling of Nf cannot be resolved due to signal to noise ratio]. ^{19}F NMR (471 MHz, DMSO- d_6): δ -80.6 (t, J = 9.4 Hz), -113.4 (t, J = 9.4 Hz), -121.1 (d, J = 9.4 Hz), -125.9 (t, J = 9.4 Hz).

In one embodiment, a process for preparing the following catalyst is shown below.



- 2,2'-((1R,2R)-1,2-Diaminoethane-1,2-diyl)diphenol (5.0 g, 19.4mmol) was charged into a 250-mL round-bottom flask followed by DCM (125 ml). To the resulting suspension was charged Et₃N (13.6 mL; 97.0 mmol) and the mixture was cooled to – 10°C.
- 5 Tf₂O (13.1 mL; 78.0 mmol) was charged slowly to maintain the internal temperature lower than 0°C. The mixture was then warmed up to room temperature and aged for 0.5h. The reaction mixture was then poured into 4% aq. NaHCO₃ solution. The organic phase was washed with 1N aq. HCl and then brine. Final organic phase was dried over Na₂SO₄ and then concentrated. The resulting crude residue was purified by silica gel chromatography to afford
- 10 the desired product in an 81% (16g) as an ethyl acetate solvate. ¹H NMR (500 MHz, d₆-DMSO): δ_H 11.14 (2H, br s), 8.01 -8.03 (2H, dd, *J* = 7.5, 2.0 Hz), 7.42-7.50 (4H, m), 7.06-7.07 (2H, d, *J* = 8.0 Hz), 5.09 (2H, br s), 4.02-4.06 (4H, q, *J* = 7.2 Hz, EtOAc), 2.00 (6h, s, EtOAc), 1.17-1.20 (6H, t, *J* = 7.2 Hz, EtOAc). ¹³C NMR (126 MHz, d₆-DMSO): δ_C 145.15, 131.32, 129.68, 128.46, 128.18, 119.31, 119.02 (q, *J* = 322 Hz), 117.66 (q, *J* = 321 Hz),
- 15 55.94. ¹⁹F NMR (471 MHz, d₆-DMSO): δ_F -74.24, -77.80.

Preparation of Compound A




- 20 To a slurry of compound 7 (20g, 18.9 mmol) in MTBE (40 mL) at room temperature was added a solution of sodium phosphate dibasic dihydrate (8.42 g, 47.3 mmol) in water (80 mL) and the resulting slurry was allowed to stir at room temperature for 40 minutes. The reaction mixture was transferred to a separatory funnel and the organic phase was collected and washed with a solution of sodium phosphate dibasic dihydrate (3.37 g,

18.91 mmol) in water (40 mL). A solution of KOH (4.99 g, 76 mmol) in water (80 mL) and methanol (10 mL) was then added to the organic phase and the resulting mixture was heated to 50°C and allowed to stir at this temperature for 6 hours. MTBE (20 mL) and water (40 mL) were then added to the reaction mixture and the resulting solution was transferred to a separatory funnel and the aqueous layer was collected and washed with MTBE (20 mL). Additional MTBE (40 mL) was added to the aqueous layer and the resulting solution was adjusted to pH 4-5 via slow addition of concentrated HCl. The resulting acidified solution was transferred to a separatory funnel and the organic phase was collected, concentrated *in vacuo* and solvent switched with acetone, maintaining a 30 mL volume. The resulting acetone solution was added dropwise to water and the precipitate formed was filtered to provide compound **A** as a white solid (10 g, 92%). ¹H NMR (500 MHz, d₆-DMSO): δ_H 12.6 (1H, s), 7.52 (1H, dd, *J* = 8.6, 1.3 Hz), 7.41 (1H, brs), 7.22 (1H, d, *J* = 7.2 Hz), 7.08-7.02 (2H, m), 6.87-6.84 (2H, m), 6.44 (1H, dd, *J* = 8.3, 1.8 Hz), 6.39 (1H, t, *J* = 2.1 Hz), 6.35 (1H, dd, *J* = 8.1, 2.0 Hz), 4.89 (1H, t, *J* = 7.3 Hz), 3.79 (3H, br s), 3.68 (3H, s), 3.47 (2H, br s), 3.39 (2H, br s), 2.96-2.93 (2H, m), 2.82-2.77 (3H, m), 2.44 (1H, dd, *J* = 14.8, 7.4 Hz).


While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, the practice of the invention encompasses all of the usual variations, adaptations and/or modifications that come within the scope of the following claims. All publications, patents and patent applications cited herein are incorporated by reference in their entirety into the disclosure.

WHAT IS CLAIMED IS:


1. A process for preparing a compound of Formula (I):



- 5 or a salt thereof, comprising contacting a compound of formula (viii):



or a salt thereof, with a catalyst of formula (V):



- 10 wherein each occurrence of R⁵ is independently selected from the group consisting of phenyl; naphthyl and pyridine; wherein each of the phenyl and naphthyl is optionally substituted with one to three substituents independently selected from halogen, -O-C₁-C₄alkyl, -CN, sulfonate, -NO₂, phosphonate, C₁-C₄alkyl optionally substituted with one to four halogens, -O-Tf, and -O-Ts-CF₃; and

- 15 each occurrence of R⁶ is independently selected from the group consisting of Tf and Nf;

in a suitable solvent for a time sufficient to form a compound of formula (I);


wherein:

- R¹ represents up to 3 phenyl group substituents, each independently selected from C₁-C₆ alkyl, C₁-C₆ haloalkyl, halo, -CN, -OH and C₁-C₆ alkoxy;
- 20 R² represents up to 3 phenyl group substituents, each independently selected from C₁-C₆ alkyl, C₁-C₆ haloalkyl, halo, -CN, -OH and C₁-C₆ alkoxy;

R³ represents up to 3 phenyl group substituents, each independently selected from C₁-C₆ alkyl, C₁-C₆ haloalkyl, halo, -CN, -OH and C₁-C₆ alkoxy; and


R⁴ is C₁-C₆ alkyl or C₃-C₇ cycloalkyl.


5 2. The process of claim 1, wherein the catalyst is a compound of formula
 (Va):




3. The process of any of claims 1 and 2, wherein each occurrence of R¹ is halo; each occurrence of R² is independently selected from halo, C₁-C₃ alkyl, C₁-C₃ alkoxy and C₁-C₃ haloalkyl; each occurrence of R³ is independently selected from C₁-C₃ alkyl and C₁-C₃ alkoxy; and R⁴ is C₁-C₆ alkyl.

4. The process of any of claims 1-3, wherein the catalyst is selected from
15 the group consisting of:





5. The process of any of claims 1-4, wherein the catalyst is selected from




6. The process of any of claims 1-5, wherein the solvent is selected from the group consisting of acetone, toluene, dichloromethane, DCE, THF, chlorobenzene, 1,2-dichlorobenzene, MTBE, CPME, acetonitrile, EtOAc, IPAc, MeOAc, nitromethane, trifluoromethylbenzene, methyl ethyl ketone, DME, anisole, hexafluorobenzene, o-xylene, fluorobenzene, 1,4-dioxane, iPr₂O and 2-MeTHF.

7. The process of claim 6, wherein the solvent is selected from toluene, MTBE, and CPME.


8. The process of any of claims 1-7, wherein said process is carried out at a temperature from about 20°C to about 60°C.

9. A process for preparing a compound of Formula (I):




(I),

or a salt thereof, comprising contacting a compound of formula (viii):



(viii),

or a salt thereof, with a catalyst of formula (VI):



(VI),

5

wherein each occurrence of R^7 is independently selected from the group consisting of phenyl, naphthyl, phenanthrenyl, pyridyl and thiophenyl, each of which is optionally substituted with one to five substituents independently selected from halogen and $-CF_3$; and

10 each occurrence of R^8 is hydrogen;

in a suitable solvent for a time sufficient to form a compound of formula (I);

wherein:

R^1 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, $-CN$, $-OH$ and C_1 - C_6 alkoxy;

15 R^2 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, $-CN$, $-OH$ and C_1 - C_6 alkoxy;

R^3 represents up to 3 phenyl group substituents, each independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halo, $-CN$, $-OH$ and C_1 - C_6 alkoxy; and


R^4 is C_1 - C_6 alkyl or C_3 - C_7 cycloalkyl.

20

10. The process of claim 9, wherein each occurrence of R^1 is halo; each occurrence of R^2 is independently selected from halo, C_1 - C_3 alkyl, C_1 - C_3 alkoxy and C_1 - C_3 haloalkyl; each occurrence of R^3 is independently selected from C_1 - C_3 alkyl and C_1 - C_3 alkoxy; and R^4 is C_1 - C_6 alkyl.


5

11. The process of any of claims 9-10, wherein the catalyst is selected from the group consisting of:



10


12. The process of any of claims 9-11, wherein the catalyst is selected from the group consisting of:



13. The process of any of claims 9-12, wherein the solvent is selected from the group consisting of CF₃-toluene, Cl-benzene, and 1,2-Cl₂-benzene.

14. The process of any of claims 9-13, wherein said process is carried out
5 at a temperature from about 50°C to about 80°C.


15. The process of any of claims 1-14, wherein the compound of formula (I) made by said process is:




10 wherein R⁴ is C₁-C₆ alkyl.

16. The process of claim 15, wherein R⁴ is methyl.

17. The process of any of claims 1-16, wherein the compound made by
15 said process is Compound (III):



18. The process of claim 17, further comprising converting Compound (III) to Compound A:



(Compound A).

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/062654

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/517; A61P 31/12; C07C 309/30; C07D 239/72; C07D 239/84 (2016.01)

CPC - C07D 239/84; C07C 309/29; C07C 309/30; C07D 239/78; C07D 239/80 (2016.11)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 31/517; A61P 31/12; C07C 309/30; C07D 239/72; C07D 239/84 (2016.01)

CPC - C07C 309/29; C07C 309/30; C07D 239/78; C07D 239/80; C07D 239/84 (2016.11)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 514/221; 514/252.17; 514/260.1; 544/283; 544/284; 544/286; 544/292; IPC(8) - A61K 31/517; A61P 31/12; C07C 309/30; C07D 239/72; C07D 239/84; CPC - C07C 309/29; C07C 309/30; C07D 239/78; C07D 239/80; C07D 239/84 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, Google Patents, Google Scholar, STN

Search terms used: human cytomegalovirus, HCMV, CMV, human herpesvirus, HHV5, medication, treatment, prophylactic, prophylaxis, inhibitor, inhibitors, inhibition, quinazoline heterocycles inhibitors of Human cytomegalovirus

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2015/0045371 A1 (AICURIS GMBH & CO KG) 12 February 2015 (12.02.2015) entire document	1-3, 9-11
A	US 2009/0221822 A1 (GOOSSEN et al) 03 September 2009 (03.09.2009) entire document	1-3, 9-11
A	WO 2015/088931 A1 (MERCK SHARP & DOHME CORP et al) 18 June 2015 (18.06.2015) entire document	1-3, 9-11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

23 December 2016

Date of mailing of the international search report

24 JAN 2017

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/062654

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 4-8, 12-18
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.